SkyWest Inc (SKYW) Stock Price Today
Aura AI Summary
Key Stats
- $3.55BMarket Cap
- 210,627Volume
- IndustrialsSector
- $115.9452W High
- $78.4052W Low
- 8 DaysTypical Hold Time
- $5.34BEnterprise Value
- -Div Yield
- -Trading Activity
Track SkyWest Inc (SKYW) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, SkyWest Inc has traded between a low of $78.4 and a high of $115.94, highlighting its annual price range. Buy and sell SkyWest Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Most Recent News
Basilea presents new data on antifungals fosmanogepix, isavuconazole, and antibiotic ceftobiprole at IDWeek 2026
Basilea Pharmaceutica announced new clinical and activity data for its antifungal drugs fosmanogepix and isavuconazole, as well as the antibiotic ceftobiprole, to be presented at IDWeek 2026 in Washington D.C. Highlights include pediatric data from f...

Gainsight launches AI-native Atlas managing $75M ARR and new value-based pricing for customer retention.
Gainsight introduced its AI-native services business, Atlas, which manages over $75 million in annual recurring revenue (ARR) by handling long-tail customer renewals with AI agents and human managers. The company also announced a shift to value-based...

Oculis to present new Phase 2 biomarker data on Privosegtor for optic neuritis at ACTRIMS-ECTRIMS 2026
Oculis Holding AG will present new biomarker analyses from its Phase 2 ACUITY trial of Privosegtor, a potential neuroprotective therapy for optic neuritis, at the 10th Joint ACTRIMS-ECTRIMS Meeting in October 2026. The data focus on plasma neurofilam...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.